AbCellera's success is unprecedented: what have we learned?
Lab Chip
; 21(12): 2330-2332, 2021 06 15.
Article
in English
| MEDLINE | ID: covidwho-1415964
ABSTRACT
The search for antibody therapeutic candidates is a timely and important challenge well-suited to lab on a chip approaches. Vancouver-based AbCellera Biologics Inc. developed a microfluidic antibody screening platform, ancillary technologies, and a service-based drug discovery business model that has proved a tremendous success. We take the opportunity here to reflect on what enabled this success. We consider the common lab on a chip motivations that were part of their success, and those that were not.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Biological Products
/
Microfluidic Analytical Techniques
Language:
English
Journal:
Lab Chip
Journal subject:
Biotechnology
/
Chemistry
Year:
2021
Document Type:
Article
Affiliation country:
D1lc00155h
Similar
MEDLINE
...
LILACS
LIS